{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:27:28Z","timestamp":1775147248611,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Laronidase is the first drug of enzyme replacement therapy approved for the treatment of mucopolysaccharidosis type I (MPS I). However, its adverse events (AEs) have not been investigated in real - world settings. The aim of this study was to investigate AEs associated with laronidase using the Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data for laronidase were acquired from the FAERS database covering Q1 2004 through Q4 2024. The Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN) and Multi-item Gamma Poisson Shrinker (MGPS) were employed to identify potential safety signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3,677 adverse event reports associated with laronidase were identified in the FAERS from 2004 to 2024. The results revealed that common AEs of laronidase such as pyrexia [n = 465, ROR = 6.23 (5.68\u20136.83)], pneumonia [n = 223, ROR = 3.22 (2.82\u20133.68)], cough [n = 167, ROR = 2.78 (2.38\u20133.23)], influenza [n = 114, ROR = 4.95 (4.12\u20135.95)], urticaria [n = 106, ROR = 2.99 (2.47\u20133.62)], disease progression [n = 101, ROR = 3.95 (3.25\u20134.81)]. Furthermore, we detected probable unexpected AEs like seizures [n = 75, ROR = 3.1 (2.47\u20133.89)], hydrocephalus [n = 60, ROR = 50.47 (39.1\u201365.14)], blindness [n = 44, ROR = 5.02 (3.73\u20136.75)], glaucoma [n = 32, ROR = 7.56 (5.34\u201310.69)]. Laronidase -induced adverse reactions involved 27 System Organ Class (SOC). No significant difference in AEs was observed between sexes for laronidase. Most AEs (n = 763) emerged more than 360 days following laronidase treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study has identified AEs associated with laronidase that could provide support for clinical monitoring and risk identification of laronidase.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1623921","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:34:23Z","timestamp":1755668063000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhuomiao","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junling","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xihui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.carpath.2017.01.001","article-title":"Progressive heart disease in mucopolysaccharidosis type I mice May be mediated by increased cathepsin B activity","volume":"27","author":"Baldo","year":"2017","journal-title":"Cardiovasc Pathol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/gim.2014.25","article-title":"The natural history of MPS I: global perspectives from the MPS I registry","volume":"16","author":"Beck","year":"2014","journal-title":"Genet. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","article-title":"Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning","volume":"121","author":"Boelens","year":"2013","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","article-title":"Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management","volume":"34","author":"Braunlin","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ymgmr.2016.07.006","article-title":"The diagnostic journey of patients with mucopolysaccharidosis I: a real-world survey of patient and physician experiences","volume":"8","author":"Bruni","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ymgme.2019.11.007","article-title":"Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study","volume":"129","author":"Chen","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/jhg.2015.155","article-title":"Demographic characteristics and distribution of lysosomal storage disorder subtypes in eastern China","volume":"61","author":"Chen","year":"2016","journal-title":"J. Hum. Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1172\/JCI34676","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J. Clin. Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jpeds.2012.07.052","article-title":"Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome","volume":"162","author":"Eisengart","year":"2013","journal-title":"J. Pediatr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymgmr.2017.01.004","article-title":"Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I","volume":"10","author":"Giugliani","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/biom11020189","article-title":"Mucopolysaccharidosis type I: current treatments, limitations, and prospects for improvement","volume":"11","author":"Hampe","year":"","journal-title":"Biomolecules"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7888","DOI":"10.3390\/ijms22157888","article-title":"Differences in MPS I and MPS II disease manifestations","volume":"22","author":"Hampe","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"CD009354","DOI":"10.1002\/14651858.CD009354.pub4","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme((R))) for treating mucopolysaccharidosis type I","volume":"6","author":"Jameson","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/S0140-6736(03)13311-9","article-title":"Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I","volume":"361","author":"Kakavanos","year":"2003","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10030161","article-title":"Mucopolysaccharidosis type I","volume":"10","author":"Kubaski","year":"2020","journal-title":"Diagn. (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3390\/diagnostics14171956","article-title":"Body height of MPS I and II patients after hematopoietic stem cell transplantation: the impact of dermatan sulphate","volume":"14","author":"Lipinski","year":"2024","journal-title":"Diagn. (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40360-025-00902-6","article-title":"Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER","volume":"26","author":"Liu","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"823044","DOI":"10.3389\/fped.2022.823044","article-title":"Case report: mucopolysaccharidosis type I treatment with alpha-L-Iduronidase replacement therapy","volume":"10","author":"Li","year":"2022","journal-title":"Front. Pediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"893239","DOI":"10.3389\/fnins.2022.893239","article-title":"Dissociation in neural correlates of hyperactive\/impulsive vs. inattentive symptoms in attention-Deficit\/Hyperactivity disorder","volume":"16","author":"Luo","year":"2022","journal-title":"Front. Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"fcae413","DOI":"10.1093\/braincomms\/fcae413","article-title":"Differential functional change in olfactory bulb and olfactory eloquent areas in parkinson's disease","volume":"6","author":"Luo","year":"2024","journal-title":"Brain Commun."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13020209","article-title":"Mucopolysaccharidosis type 1 among children-neuroradiological perspective based on single centre experience and literature review","volume":"13","author":"Machnikowska-Sokolowska","year":"2023","journal-title":"Metabolites"},{"key":"B23","doi-asserted-by":"publisher","first-page":"110137","DOI":"10.1016\/j.ijporl.2020.110137","article-title":"Otorhinolaryngological manifestations in 61 patients with mucopolysaccharidosis","volume":"135","author":"Murgasova","year":"2020","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ajmg.a.63029","article-title":"18-year follow-up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I","volume":"191","author":"Pjetraj","year":"2023","journal-title":"Am. J. Med. Genet. A"},{"key":"B25","doi-asserted-by":"publisher","first-page":"801147","DOI":"10.3389\/fcvm.2021.801147","article-title":"Progression of cardiovascular manifestations in adults and children with mucopolysaccharidoses with and without enzyme replacement therapy","volume":"8","author":"Poswar","year":"2021","journal-title":"Front. Cardiovasc Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"124355","DOI":"10.1016\/j.ijpharm.2024.124355","article-title":"Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration","volume":"660","author":"Schuh","year":"2024","journal-title":"Int. J. Pharm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","article-title":"Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment","volume":"116","author":"Shapiro","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ymgme.2012.07.016","article-title":"An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT)","volume":"107","author":"Shapiro","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"B29","first-page":"88","article-title":"Alpha-L-iduronidase (Laronidase; aldurazyme)","volume":"45","year":"2003","journal-title":"Med. Lett. Drugs Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/ajmg.a.32320","article-title":"Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis?","author":"Vieira","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"B33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","article-title":"Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: a comprehensive meta-analysis of pooled data from multiple studies","volume":"117","author":"Xue","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.braindev.2019.01.008","article-title":"Early enzyme replacement therapy enables a successful hematopoietic stem cell transplantation in mucopolysaccharidosis type IH: Divergent clinical outcomes in two Japanese siblings","volume":"41","author":"Yamazaki","year":"2019","journal-title":"Brain Dev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.3390\/ijms23094785","article-title":"Nanoemulsions as gene delivery in mucopolysaccharidosis type I-A mini-review","volume":"23","author":"Zapolnik","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1623921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:34:24Z","timestamp":1755668064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1623921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":35,"alternative-id":["10.3389\/fphar.2025.1623921"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1623921","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"1623921"}}